Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study

Arthritis and Rheumatology

Volumn 66, Issue 2, 2014, Pages 379-389

  Furie, Richard ^a   Nicholls, Kathy ^b   Cheng, Tien Tsai ^c   Houssiau, Frederic ^d   Burgos Vargas, Ruben ^e   Chen, Shun Le ^f   Hillson, Jan L ^g   Meadows Shropshire, Stephanie ^g   Kinaszczuk, Michael ^g   Merrill, Joan T ^h  

^a North Shore LIJ Health System Division of Rheumatology and Allergy Clinical Immunology ^*  (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g BRISTOL MYERS SQUIBB   (United States)

^h OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; DOUBLE STRANDED DNA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; PROTEIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; ASIAN; BACTERIAL PERITONITIS; BRONCHOPNEUMONIA; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; GLOMERULUS FILTRATION RATE; HEART FAILURE; HERPES ZOSTER; HUMAN; INTERSTITIAL PNEUMONIA; KIDNEY FUNCTION; LUNG ABSCESS; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALARIA; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SHORT FORM 36; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; URINE SEDIMENT; VISUAL ANALOG SCALE;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONALITY; LONGITUDINAL STUDIES; LUPUS NEPHRITIS; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84896274377     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38260     Document Type: Article

References (35)

1. Foster MH. T cells and B cells in lupus nephritis. Semin Nephrol 2007;27: 47-58.
2. Orencia (abatacept) prescribing information. Princeton (NJ): Bristol-Myers Squibb; 2013. URL: http://packageinserts.bms.com/pi/ pi-orencia.pdf.
3. Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ. Abatacept binds to the Fc receptor CD64 but does not mediate complementdependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol 2007;34: 2204-10.
4. Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006;33: 2162-6.
5. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997;159: 3104-8.
6. Daikh DI, Wofsy D. Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166: 2913-6.
7. Schiffer L, Sinha J, Wang X, Huang W, von Gersdorff G, Schiffer M, et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003;171: 489-97.
8. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, doubleblind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63: 939-48.
9. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62: 3077-87.
10. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44: 902-6.
11. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. 2nd ed. Lincoln (RI): QualityMetric; 2000.
12. Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study [abstract]. Arthritis Rheum 2011;63 Suppl:S962-3.
13. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25: 1271-7.
14. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-50.
15. Churg J, Sobin H. Renal disease: classification and atlas of glomerular disease. Tokyo: Igaku-Shoin; 1982.
16. Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept in lupus nephritis [abstract]. Ann Rheum Dis 2012 Suppl 3;71:534.
17. Wofsy D, Meadows Shropshire S, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative outcome measures support opposing interpretations of data from a multicenter, randomized, double-blind, placebo-controlled phase II/III study [abstract]. Arthritis Rheum 2011;63 Suppl:S964-5.
18. Wofsy D, Meadows-Shropshire S, Hillson JL, Diamond B. Comparative analysis of alternative outcome measures for use in lupus nephritis trials [abstract]. Ann Rheum Dis 2012 Suppl 3;71:535.
19. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012;64: 3660-5.
20. Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum 2013;65: 1586-91.
21. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54: 421-32.
22. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39: 363-9.
23. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46: 1121-3.
24. US Food and Drug Administration. Guidance for industry. Systemic lupus erythematosus-developing medical products for treatment. June 2010. URL: URL:http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ ucm072063.pdf.
25. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20: 1103-12.
26. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al, for the Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343: 1156-62.
27. Chan TM, Tse KC, Tang CS, Mok MY, Li FK, for the Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2013;16: 1076-84.
28. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353: 2219-28.
29. Houssiau F, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46: 2121-31.
30. Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012;14:R33.
31. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al, for the LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64: 1215-26.
32. Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 2013;65: 2368-79.
33. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor - inhibition. N Engl J Med 2005;353: 1114-23.
34. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144: 865-76.
35. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68: 1870-7.